Financials in millions USD. Fiscal year is February - January.
Breakdown
TTM
06/30/2025
06/30/2024
06/30/2023
06/30/2022
06/30/2021
Revenue
0
0
0
0
7
0
Revenue Growth (YoY)
--
--
--
-100%
--
--
Cost of Revenue
--
--
--
--
--
--
Gross Profit
--
--
--
--
--
--
Selling, General & Admin
3
3
3
3
4
5
Research & Development
7
7
8
12
8
3
Operating Expenses
9
9
10
14
13
7
Other Non Operating Income (Expenses)
--
--
--
--
--
--
Pretax Income
-9
-9
-9
-14
-5
-7
Income Tax Expense
0
0
0
0
0
0
Net Income
-9
-9
-9
-14
-5
-7
Net Income Growth
0%
0%
-36%
180%
-28.99%
133%
Shares Outstanding (Diluted)
225.56
204.95
179.63
145.09
143.27
130.42
Shares Change (YoY)
25%
14%
24%
1%
10%
24%
EPS (Diluted)
-0.04
-0.04
-0.05
-0.09
-0.03
-0.05
EPS Growth
-17%
-16%
-45%
159%
-36%
70%
Free Cash Flow
-8
-8
-9
-14
-3
-5
Free Cash Flow Per Share
--
--
--
--
--
--
Gross Margin
--
--
--
--
--
--
Operating Margin
0%
0%
0%
0%
-85.71%
0%
Profit Margin
0%
0%
0%
0%
-71.42%
0%
Free Cash Flow Margin
0%
0%
0%
0%
-42.85%
0%
EBITDA
-9
-9
-9
-14
-6
-7
EBITDA Margin
0%
0%
0%
0%
-85.71%
0%
D&A For EBITDA
0
0
0
0
0
0
EBIT
-9
-9
-9
-14
-6
-7
EBIT Margin
0%
0%
0%
0%
-85.71%
0%
Effective Tax Rate
0%
0%
0%
0%
0%
0%
Follow-Up Questions
What are Cynata Therapeutics Ltd's key financial statements?
What are the key financial ratios for CYYNF?
How is Cynata Therapeutics Ltd's revenue broken down by segment or geography?
Is Cynata Therapeutics Ltd profitable?
Does Cynata Therapeutics Ltd have any liabilities?
How many outstanding shares for Cynata Therapeutics Ltd?
Key Stats
Prev.Close
$0.15
Open
$0.15
Day's Range
$0.11 - $0.15
52 week range
$0.08 - $0.15
Volume
220
Avg.Volume
32
EPS (TTM)
-0.03
Dividend yield
--
Market Cap
$35.6M
What is CYYNF?
Cynata Therapeutics Ltd. engages in the development and commercialization of therapeutic products. The firm is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology. Cymerus uses induced pluripotent stem cells (iPSCs) to manufacture cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale. Its product candidates include CYP-001, CYP-004 and CYP-006TK. CYP-001 is under Phase II clinical trials with a focus on treatment for steroid-resistant acute graft versus host disease (GvHD) and a Phase 1/II trial in patients undergoing kidney transplantation. CYP-006TK is a Cymerus iPSC-derived MSC topical wound dressing product candidate. This product is used in the Company’s Phase I clinical trial in diabetic foot ulcers (DFU). CYP-004, is an iPSC-derived MSC product for intra-articular injection (injection into a joint), is ongoing with a Phase III trial in patients with osteoarthritis of the knee.